CBLL — CeriBell, Inc.

CeriBell, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $24.8 million, up 34% year-over-year from $18.5 million.
• Full Year Revenue: $89.1 million, reflecting a 36% increase over 2024.
• Gross Margins: 87% for Q4 and 88% for the full year, slightly down from 88% in Q4 2024 due to increased tariffs on products from China.
• Active Accounts: 647 as of December 31, 2025, with 32 net new accounts added in Q4 and 118 throughout the year.
• Net Loss: $13.5 million in Q4 ($0.36 per share), compared to a loss of $12.6 million ($0.40 per share) in Q4 2024. Full year net loss was $53.4 million ($1.46 per share), up from a loss of $40.5 million ($3.39 per share) in 2024.
• Cash Position: $159.3 million as of December 31, 2025.

2. Strategic Updates and Business Highlights:

• CeriBell expanded its total addressable market from $2 billion to over $3.5 billion by penetrating the core seizure market and launching new products for neonate and pediatric patients.
• Achieved FDA clearance for seizure detection products for neonates and a delirium detection algorithm, positioning CeriBell as a leader in point-of-care EEG technology.
• Expanded commercial infrastructure from 35 to 55 territories, with a strong backlog of accounts interested in adopting the technology.
• The company aims to make EEG a new vital sign in acute care settings, with plans for further integration of delirium and stroke monitoring capabilities.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $111 million and $115 million, representing a growth of 25% to 29% over 2025.
• Anticipates modest revenue impact from the full launch of neonate and pediatric products in Q2 2026, with significant contributions expected in 2027.
• Plans to leverage existing commercial infrastructure for new product launches, minimizing the need for substantial new investments.

4. Bad News, Challenges, or Points of Concern:

• Operating expenses increased significantly by 42% in 2025 due to investments in commercial organization and legal expenses, which may pressure margins.
• The company expects gross margins to remain in the mid-80% range throughout 2026, affected by tariffs and operational costs.
• The sales cycle for new product launches, particularly in the neonate market, may delay revenue recognition, with financial impacts not expected until Q4 2026.
• Ongoing litigation with Natus could lead to increased expenses and uncertainty in the near term.

5. Notable Q&A Insights:

• Management acknowledged a conservative approach to 2026 guidance, emphasizing the need to deliver on projections while recognizing potential upside from account growth and utilization.
• Discussions around the commercial plan for delirium highlighted a focus on existing accounts, with expectations of deeper penetration and increased utilization.
• The company is exploring system-wide sales strategies to accelerate account acquisition, particularly in larger hospital systems.
• There is cautious optimism regarding pricing strategies for headbands and potential price increases, with a commitment to maintaining pricing discipline amid macroeconomic pressures.

Overall, CeriBell, Inc. demonstrated strong growth in 2025 and laid a solid foundation for future expansion, despite facing challenges related to operating expenses and market entry timelines.